Table 5.

Trials/studies involving Ostalmovir.

Study type	Trial outcome and design	Conclusion	Comments
Case series [37]	Out of 115 COVID-19 confirmed case, 5 patients found co-infected with influenza virus and followed up.	Patient with both COVID‐19 and influenza virus co-infection did not appear to show a more severe condition.	Small sized case series.
	All patients received antiviral therapy (including Ostalmovir), antibacterial, and supportive therapy (when indicated).		Multiple therapies used, thus cannot confirmed the efficacy of Ostalmovir against COVID-19.
	None of the patients taken to intensive care unit recovered and discharged from hospital with no death.
Descriptive study [38]	Of 99 COVID-19 cases admitted to the hospital. 76% received antivirals (including Ostalmovir, ganciclovir, and lopinavir/ritonavir tablets. The duration of antiviral treatment was 3–14 days. While 70% of them treated with antibiotics. Upon results, 58% of patients remained hospitalized, 31% discharged, and 11% had died.	The infection of 2019-nCoV was of clustering onset, is more likely to infect older men with comorbidities, and can result in severe and even fatal respiratory diseases such as ARDS.	Retrospective case series with small sample size not enough to support clinical decision.